Information on the EQA test Tumour cytogenetics
Aim
The ring trail aims at the evaluation of the entire process of the chromosome banding analysis in haematological neoplasias starting with the receipt of the sample and ending with the outgoing report.
Performance interval
Once per year.
Procedure
A surrogate blood sample is generated by using cell lines. The sample is sent out with a fictitious request. The request includes a diagnostic question, which needs to be answered by a chromosome banding analysis.
Method
The analysis has to be carried out according to the own laboratory standard operational procedures. For evaluation, the findings have to be submitted in a written diagnostic report.
Criteria
Proof of target aberrations through chromosome banding analysis, correct karyotype, correct report of findings.
The identification of a defined target aberration is prerequisite to attest a successful participation in the EQA test.
The identification of a defined target aberration is prerequisite to attest a successful participation in the EQA test.
Certificate
A certificate will be provided that states the (successful) participation in the trial. The certificate is valid for two years.
EQA test supervisor
Prof. Dr. med. Gudrun Göhring
amedes MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie Hannover
Georgstr. 50
30159 Hannover
amedes MVZ wagnerstibbe für Laboratoriumsmedizin, Hämostaseologie, Humangenetik und Mikrobiologie Hannover
Georgstr. 50
30159 Hannover
Dr. rer. nat. Sarah Volpert
MVZ Institut für Labormedizin und klinische Genetik Rhein/Ruhr GmbH
Willy-Brandt-Platz 4
45127 Essen
If you would like to contact the EQA test supervisor(s), please call or e-mail the Coordination Office QA of BVDH:
Phone: +49 2403 83 80 54
E-mail: brandt@bvdh.de
Status as of: May/2020